Why Aspen Aerogels (ASPN) Is Down 52.6% After Slashing Guidance and Taking a Major Impairment Charge

• Aspen Aerogels recently reported third quarter 2025 financial results that included a sharp year-over-year drop in revenue to US$73.02 million and a net loss of US$6.33 million, while revising full-year 2025 guidance downward due to continuing challenges in the electric vehicle market.
• The company incurred a very large impairment charge on property, plant, and equipment and announced new leadership appointments to address sector headwinds and operational efficiency, signaling a pivot toward cost control and new market opportunities.
• We'll examine how Aspen Aerogels' lowered revenue outlook and costly impairment charge affect its future investment narrative and recovery prospects.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Aspen Aerogels Investment Narrative Recap

To own Aspen Aerogels stock today, you must believe in the company's ability to stabilize and reignite growth across both its EV Thermal Barrier and Energy Industrial segments, even as near-term electric vehicle demand remains soft. The recent downward revision in full-year 2025 revenue guidance and steep impairment charge directly impact the short-term outlook, intensifying concerns over continued customer concentration and reliance on recovery in the EV market as the biggest catalyst and greatest risk to the business, respectively.

Of recent events, Aspen’s lowered revenue and profit guidance for 2025 stands out, signaling that near-term market headwinds in the EV segment may persist longer than anticipated. This adjustment not only sets a more cautious tone for short-term performance but also puts additional weight on the importance of execution in operational efficiency and diversification efforts to support any future rebound.

By contrast, investors should keep in mind the increased risk tied to high customer concentration in the EV Thermal Barrier segment, especially as...

Read the full narrative on Aspen Aerogels (it's free!)

Aspen Aerogels' outlook anticipates $513.3 million in revenue and $62.9 million in earnings by 2028. This scenario assumes an annual revenue growth rate of 8.9% and a turnaround in earnings from a current loss of $311.9 million to a positive $62.9 million, an improvement of $374.8 million.

Uncover how Aspen Aerogels' forecasts yield a $8.75 fair value, a 127% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community range widely from US$6.83 to US$52.18 per share. While community views differ, current weakness in EV demand continues to test Aspen’s short-term recovery, inviting you to explore these varied assessments for yourself.

Explore 10 other fair value estimates on Aspen Aerogels - why the stock might be worth just $6.83!

Build Your Own Aspen Aerogels Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Aspen Aerogels research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Aspen Aerogels research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aspen Aerogels' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com